Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | GCLC | P48506 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704445 | 0.89 | TP53 (0.32) | GAAGCLC | |
| SCHEMBL1705128 | 0.88 | GAA (0.32) | GAACA1LMNAGCLC | |
| SCHEMBL6893526 | 0.87 | CA1 (0.32) | GAACA1 | |
| SCHEMBL17343036 | 0.85 | GCLC (0.35) | GAAGCLC | |
| SCHEMBL6890549 | 0.84 | CA2 (0.40) | ALDH1A1LMNA | |
| SCHEMBL13330433 | 0.83 | APP (0.41) | ALDH1A1LMNA | |
| SCHEMBL6893523 | 0.83 | ATR (0.36) | CA1 | |
| SCHEMBL8967538 | 0.83 | — | — | |
| SCHEMBL17369606 | 0.81 | LMNA (0.41) | CA1ALDH1A1LMNA | |
| SCHEMBL23222194 | 0.81 | GAA (0.30) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103261330-A | Ionic gelling agent, gel, process for production of gel, and crosslinking agent | KANTO KAGAKU | 2013-08-21 | — | — | CN | claimed |
| CN-1058399-A | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | MERRELL DOW PHARMA (US) | 1992-02-05 | — | — | CN | claimed |
| US-3966727-A | Manufacture of phthalo-bis-guanamines | BASF AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | claimed |
| US-3933866-A | Process for the manufacture of amino-anthraquinones | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | claimed |
| US-20250233206-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12315883-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-05-27 | — | — | US | disclosed |
| US-12261265-B2 | Method for producing lithium fluorosulfonate, lithium fluorosulfonate, nonaqueous electrolytic solution, and nonaqueous electrolytic solution secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-03-25 | — | — | US | disclosed |
| US-20230395857-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11791499-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-10-17 | — | — | US | disclosed |
| EP-4219400-A2 | METHOD FOR PRODUCING LITHIUM FLUOROSULFONATE, LITHIUM FLUOROSULFONATE, USE OF LITHIUM FLUOROSULFONATE IN A NONAQUEOUS ELECTROLYTIC SOLUTION, AND NONAQUEOUS ELECTROLYTIC SOLUTION | Mitsubishi Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11695155-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20230155178-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-1058399-A | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | MERRELL DOW PHARMA (US) | 1992-02-05 | — | — | CN | disclosed |
| EP-0003205-B1 | PROCESS FOR THE PREPARATION OF ETHYLESTERS | RHONE-POULENC INDUSTRIES (FR) | 1981-03-25 | — | — | EP | disclosed |
| EP-0003205-A1 | Process for the preparation of ethylesters | RHONE-POULENC INDUSTRIES (FR) | 1979-07-25 | — | — | EP | disclosed |
| US-4009154-A | Process for preparing aromatic polyamides with sodium carbonate hydrate as acid acceptor | TEIJIN LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3991016-A | Poly(1,4-benzamide) copolymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
| US-3966727-A | Manufacture of phthalo-bis-guanamines | BASF AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | disclosed |
| US-3951914-A | Process for preparing poly(1,4-benzamide) in cyclic sulfone media | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
| US-3933866-A | Process for the manufacture of amino-anthraquinones | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11695155-B2 | Non-aqueous electrolytic solution and non-aqueous electrolyte secondary battery using the same | PTPN1, TP53RK, VDAC1 | GAA 3551/4885CA1 70/4885ALDH1A1 2745/4885 |
| US-20230155178-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | PTPN1, TP53RK, VDAC1 | GAA 3551/4885CA1 70/4885ALDH1A1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.